Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Comparing 3 Schedules of Alimta Plus Gemzar
- Conditions
- Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasms
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034606
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
- Conditions
- Colorectal Cancer
- First Posted Date
- 2002-05-02
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034619
- Locations
- 🇺🇸
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)", Spokane, Washington, United States
Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 326
- Registration Number
- NCT00034580
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
- Conditions
- Urologic Neoplasms
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034593
- Locations
- 🇫🇷
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.", Paris Cedex 14, France
🇩🇪For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Homburg/Saar, Germany
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- Biological: gp75 DNA vaccine
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT00034554
- Locations
- 🇺🇸
ImClone Investigational Site, New York, New York, United States
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT00034541
- Locations
- 🇺🇸
ImClone Investigational Site, Indianapolis, Indiana, United States
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
- Conditions
- MetastasesCancer
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034463
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., San Antonio, Texas, United States
A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis
- Conditions
- Sepsis
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 466
- Registration Number
- NCT00034476
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
- Conditions
- Breast Neoplasms
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034489
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
- Conditions
- Colorectal Cancer
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034502
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Munchen, Germany